Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study

Deshayes, Emmanuel; Forges, Hélène de; Fraisse, Julien; Eberlé, Marie-Claude; Guillemard, Sylvette; Fallières, Anne; Pouget, Jean‐Pierre; Tétreau, Raphaël; Kotzki, Pierre‐Olivier; Santoro, Lore; Sénesse, Pierre; Flori, Nicolas

doi:10.1016/j.clnu.2018.08.033

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Nutrition support should not be withheld for the concern that the use of nutrition support will promote tumor growth, as studies are lacking to support this. 58 Micronutrient deficiencies can be screened and assessed for part of a comprehensive assessment, including biochemical data, and an NFPE. Corrections of micronutrients before surgery should be a priority because untreated micronutrient deficiencies, such as iron, thiamin, vitamin B 12 , or vitamin D deficiency, can lead to undesired postoperative complications.…”

Section: Assessment and Diagnosismentioning

confidence: 99%

“…The use of nutrition support should be considered in individuals who are malnourished and unable to meet estimated nutrient needs for an extended period of time 8 . Nutrition support should not be withheld for the concern that the use of nutrition support will promote tumor growth, as studies are lacking to support this 58 …”

Section: Prehabilitation With a Nutrition Componentmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of nutrition components within prehabilitation programs in gastrointestinal cancers: Is prehab worth the hype?

Yaceczko,

Baltz

2023

Nut in Clin Prac

View full text Add to dashboard Cite

Nutrition impact symptoms and unintended weight loss are prevalent in patients with gastrointestinal cancers, especially during the perioperative period or while prescribed anticancer treatments. Because patients may experience loss of lean body mass and malnutrition, aggressive nutrition intervention prior to surgery should be considered. Cancer prehabilitation is a process spanning the care continuum from diagnosis to the time of surgery encompassing nutrition support, psychological and physical assessment, and targeted interventions. Thirteen studies published between 2013 and 2023 were included in this review and evaluated prehabilitation programs’ impact on postoperative outcomes in patients with gastrointestinal cancers. Literature continues to emerge supporting the integration of nutrition into a prehabilitation program because of its potential to contribute to improved clinical outcomes, quality of life, and cost‐effectiveness, but considerable variation exists with respect to the specific recommendations provided by current prehabilitation programs.

show abstract

Section: Assessment and Diagnosismentioning

confidence: 99%

Section: Prehabilitation With a Nutrition Componentmentioning

confidence: 99%

Evaluation of nutrition components within prehabilitation programs in gastrointestinal cancers: Is prehab worth the hype?

Yaceczko,

Baltz

2023

Nut in Clin Prac

View full text Add to dashboard Cite

show abstract

Home Parenteral Nutrition in Patients with Advanced Cancer: A Systematic Review and Meta-Analysis

O’Hanlon

Fragkos

Fini

et al. 2020

Nutrition and Cancer

View full text Add to dashboard Cite

The use of home parenteral nutrition (HPN) in patients with incurable cancer remains controversial with significant variation worldwide. We aimed to systematically evaluate the literature from 1960 to 2018 examining the use of HPN in advanced cancer patients for all intestinal failure indications and assess the potential benefits/burdens of HPN in this cohort of patients. The primary end point was survival and secondary end points were quality of life and nutritional/performance status. Meta-analysis was performed with a random effects model, where suitable. Of 493 studies retrieved, 22 met the quality inclusion criteria. Studies were mainly conducted in Western countries (Italy, USA, Canada, Germany), including a total of 3564 patients (mean age 57.8 years). Mean duration for HPN was 5.0 months. Mean overall survival was 7.3 months. Patients with improved performance status survived for longer on HPN. Quality of life was sparsely reported though there was no observed negative impact of PN. HPN-related complications were reported in eight studies only and were mainly catheterrelated blood stream infections. In conclusion, HPN is used for several indications in advanced cancer, though there is significant heterogeneity of results. Disparities in geographical distribution of the studies may reflect variation in accessing HPN.

show abstract

Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study

Cited by 2 publications

References 27 publications

Evaluation of nutrition components within prehabilitation programs in gastrointestinal cancers: Is prehab worth the hype?

Evaluation of nutrition components within prehabilitation programs in gastrointestinal cancers: Is prehab worth the hype?

Home Parenteral Nutrition in Patients with Advanced Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About